SARcode Raises $25 Million

SARcode Corp., a San Francisco-based developer of LFA-1 inhibitors to treat inflammatory diseases, has raised $25 million in Series A funding co-led by Alta Partners and Clarus Ventures. The company had called down $5 million of the deal as of January 2, according to a regulatory filing.